SynthesisFrontiers in endocrinology2025
Efficacy and safety of Qingre Lishi decoction for type 2 diabetes: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Qingre Lishi decoction (QRLSD) for type 2 diabetes (T2D), thereby providing new evidence-based insights into the role of traditional Chinese medicine in treating T2D. Methods: WanFang, Embase, Web of Science, PubMed, China National Knowledge Infrastructure, and the Cochrane Library were searched up to January 2025. Studies assessing the efficacy and safety of QRLSD in treating T2D were included. Data were pooled using standardized mean difference (SMD) and risk ratio (RR). Sensitivity and subgroup analyses were performed to assess the stability of the results and investigate potential sources of heterogeneity. Statistical analyses were conducted using RevMan 5.4 and Stata 18.0. Results: A total of 18 randomized controlled trials (RCTs) were included. Our results showed that QRLSD reduced the levels of fasting blood glucose (SMD: -15.09; 95% CI: [-18.27, -11.90], I² = 99%, P < 0.00001), 2-hour postprandial blood glucose (SMD: -17.71; 95% CI: [-21.70, -13.71], I² = 98%, P < 0.00001), glycated hemoglobin (SMD: -18.93; 95% CI: [-22.77, -15.09], I² = 98%, P < 0.00001), as well as other metabolic parameters, indicators of insulin resistance, and body mass index. No significant difference in the incidence of adverse events between the intervention and control groups was found (RR: 1.8; 95% CI: [0.57, 5.68], I² = 9%, P=0.32). Conclusion: For T2D, QRLSD can significantly improve clinical outcomes and may serve as a more effective therapy than single Western medicine therapy. Moreover, it was not related to significant adverse events. Given the inherent limitations of this study, large-scale, multicenter international RCTs are needed to further validate these findings in the future. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251000585.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.